• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Mycamine (micafungin sodium) for injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2011

  

Summary View

   

ADVERSE REACTIONS

Postmarketing Adverse Reactions
  • Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis
  • Blood and lymphatic system disorders: disseminated intravascular coagulation